Windtree Therapeutics is a biopharmaceutical company that is focused on the development of therapeutic solutions for acute cardiovascular and pulmonary diseases. Its lead development programs include istaroxime, AEROSURF, Lyophilized KL4 surfactant, and Rostafuroxin which are all at different stages of clinical trials. The company also has collaborations with Universita degli Studi di Milano-Bicocca, Laboratorios del Dr. Esteve, S.A., and Battelle Memorial Institute for the development of its ADS for use in its phase III program.